Metabolic management of cancer

[gdpawel]

DCA only produces "benefits" in patients who also receive real chemotherapy.

The primary reason for Her2/neu testing in breast cancer is to determine who is most likely to benefit from Herceptin, which is directed against the Her/neu protein. However, the potential benefits and risks of Herceptin have renewed concerns about the reliability of Her2/neu testing and oncologists should be concerned about it. Some studies have shown that the test produces false positives as often as 26% of the time, and may also carry some risk of false negatives.

Aetna and United Healthcare put out an announcement a few years ago that said if there’s uncertainty about the accuracy of a test that breast-cancer patients get, the insurer will cover a do-over. The insurers were trying to draw more attention to the issue. They certainly were trying to promote awareness of the problem, and if there is uncertainty, then repeat it.